炎症
Online ISSN : 1884-4006
Print ISSN : 0389-4290
ISSN-L : 0389-4290
Indometacin farnesilのヒトB細胞免疫グロブリン産生に対する抑制作用
―特にbucillamine・注射金剤との相互作用―
広畑 俊成柳田 たみ子
著者情報
ジャーナル フリー

1997 年 17 巻 6 号 p. 565-571

詳細
抄録
Indometacin farnesil (IMF) is a prodrug of indomethacin (IND) designed to reduce the occurrence of side-effects by esterification of the carboxyl group on IND with farnesol (FAR) . Previous studies have shown that IMF has characteristics of disease modifying anti-rheumatic drug in that it has a component of slow acting effect in treatment of rheumatoid arthritis patients. We therefore examined the effects of IMF on human B cells. Ig production was induced from highly purified B cells obtained from healthy donors by stimulation with Staphylococcus aureus Cowan I (SA) plus IL-2. At pharmacologically attainable concentrations, IMF, but not IND, suppressed the production of IgM and IgG. Of note, IMF, but not IND, showed additive suppressive effects on the B cell Ig production in the presence of either intramolecular disulfide form of bucillamine (SA-981) or gold sodium thiomalate. FAR showed similar suppressive effects on B cells to those of IMF.
These results indicate that IMF suppresses the human B cell functions by a different mechanism from that of bucillamine or gold sodium thiomalate. Thus, the data suggest that IMF may enhance the antirheumatic effects of bucillamine or gold sodium thiomalate.
著者関連情報
© 日本炎症・再生医学会
前の記事 次の記事
feedback
Top